Compare Incyte Corporation (INCY) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Total International Stock Index Fund ETF — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Vanguard Total International Stock Index Fund ETF trades at $84.82 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 29.1× Incyte Corporation's market cap, and Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| INCY | VXUS | |
|---|---|---|
Market Cap | $22.85B | $665.70B |
Volume | 1,927,029 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $129.93 | $88.41 |
52-Week Low | $83.80 | $72.17 |
Typical Hold Time | 33 Days | 55 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
VXUS, the Vanguard Total International Stock ETF, trades at $84.1, down 0.8% over 24 hours, with a bearish technical signal from moving averages and oscillators. Key support lies at $83, while resistance is at $85. The ETF provides diversified exposure to international equities outside the U.S., though specific financial ratios are not available in the provided data.
The outlook for VXUS is mixed; it offers broad international diversification, which can hedge against U.S. market downturns, but faces risks from global economic volatility and currency fluctuations. Recent news highlights its role in long-term portfolios, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
